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The recent series of large genome-wide association studies inEuropean andJapanese cohorts established that
Parkinsondisease (PD)hasasubstantialgeneticcomponent.To further investigate thegenetic landscapeofPD,
weperformedagenome-widescan in the largest todateAshkenaziJewishcohortof 1130Parkinsonpatientsand
2611 pooled controls. Motivated by the reduced disease allele heterogeneity and a high degree of identical-by-
descent (IBD) haplotype sharing in this founder population,we conducted a haplotype association study based
onmappingof shared IBDsegments.Weobserved significant haplotype association signals at threepreviously
implicatedParkinson loci:LRRK2 (OR 5 12.05,P 5 1.23 3 10256),MAPT (OR 5 0.62,P 5 1.78 3 10211) andGBA
(multiple distinct haplotypes, OR > 8.28, P 5 1.13 3 10211 and OR 5 2.50, P 5 1.22 3 1029). In addition, we
†Present address: New York Genome Center, New York, NY, USA.
‡These authors contributed equally.
}Present address: Weizmann Institute of Science, Rehovot, Israel.
§Present address: Department of Genetics and Genomic Sciences, Mt. Sinai School of Medicine, New York, NY, USA.
∗To whom correspondence should be addressed at: Department of Computer Science, Fu School of Engineering, Columbia University, 505 Computer
Science Building, 500 W 120th Street, Mailcode 0401, New York, NY 10027, USA. Tel: +1 2129397135; Fax: +1 2126660140; Email: itsik@cs.
columbia.edu
# The Author 2014. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Human Molecular Genetics, 2014, Vol. 23, No. 17 4693–4702
doi:10.1093/hmg/ddu158
Advance Access published on May 19, 2014
identified a novel association signal on chr2q14.3 coming from a rare haplotype (OR 5 22.58, P 5 1.21 3 10210)
and replicated it in a secondary cohort of 306 Ashkenazi PD cases and 2583 controls. Our results highlight the
power of our haplotype association method, particularly useful in studies of founder populations, and reaffirm
the benefits of studying complex diseases in Ashkenazi Jewish cohorts.
INTRODUCTION
Parkinson disease (PD; OMIM: #168600) is a common neurode-
generative disorder, affecting0.5–1% of the population in the
65–69 age group and 1–3% of individuals 80 years of age and
older (1). Causes of PD remain largely unknown, and the major-
ity of patients do not report a family history of PD. Recent esti-
mates of heritability of PD based on genome-wide complex trait
analysis are between 0.16 and 0.49 (median 0.23), depending on
the cohort (2). Causal mutations have been identified in .10
genes, and the recent string of large genome-wide association
studies (GWASs) in European and Japanese cohorts found
.30 genes and susceptibility loci associated with this disease
(3–7).
We here investigate the genetic component of PD in Ashken-
azi Jews, a well-characterized, homogeneous founder popula-
tion particularly useful in genetic studies of diseases (8,9) and
an important patient population in its own right. Improved
control for population stratification (10,11) and reduced allelic
heterogeneity facilitate identification of disease-associated var-
iants in Ashkenazi Jews. About a third of Ashkenazi PD cases
carry a mutation in either the leucine-rich repeat kinase 2
(LRRK2) or b-glucocerebrosidase (GBA) genes (12). The
p.G2019S mutation in the LRRK2 gene occurs in 9.9–14.8%
of Ashkenazi cases and 1.3–2.4% controls, compared with
2.7–3.1% of non-Jewish European cases and 0.4% of respective
controls (13–15). Mutations in the GBA gene occur in 13.7–
17.9% of Ashkenazi cases and 4.2–6.3% controls, compared
with 5 and ,1% of non-Jewish European cases and controls
(12,16–18). The most frequent of these mutations is p.N370S
(10.9% Ashkenazi cases, 5.9% controls) also present are
c.84dupG (84GG, 1.9% cases, 0.2% controls) and p.R496H
(1.67% cases, not observed in controls) (12,18,19). Another ad-
vantageous genetic feature of this founder population is the high
frequency of identical-by-decent (IBD) segments sharing among
apparently unrelated Ashkenazim (20), which facilitates detec-
tion and analysis of disease-associated haplotypes.
We performed a GWAS in an Ashkenazi Jewish cohort of
1130 Parkinson patients collected by a consortium of institutions
from New York and Tel Aviv and 2611 pooled controls. This is to
date the largest study of PD in this or any other founder popula-
tion. We conducted a genome-wide scan using a haplotype asso-
ciation method DASH (21), and concurrently, we analyzed the
association of SNPs imputed using a custom Ashkenazi refer-
ence panel (22). Both approaches identify three genome-wide
significant loci: LRRK2, MAPT and GBA. Analysis based on
IBD segments refines the association signal from SNP-based
analysis and implicates a novel genome-wide significant rare
haplotype located on chr2q14.3, which we replicated in a sec-
ondary cohort of 306 Ashkenazi PD cases and 2583 controls.
We further replicated three previously published Parkinson
loci,SNCA,MCCC1/LAMP3 andPARK16. Phenotypic variance
explained by genome-wide significant and replicated loci is
16.5% using IBD segments and 10.9% using SNP markers, com-
pared with 6–7% in Europeans (3). Our findings reaffirm the
benefits of using the Ashkenazi Jewish founder population in
studies of complex diseases and highlight the power of our
haplotype association method, which is particularly useful in
genetic studies of founder populations.
RESULTS
We analyzed genome-wide association of shared IBD segments
identified by the use of GERMLINE (23) and clustered using
DASH (21). We concurrently analyzed association of imputed
SNPs using EMMAX (24), a mixed model well suited to studies
of populations with high degree of cryptic relatedness (25), as is
the case with Ashkenazi Jews. Association results summarized
as Manhattan and QQ plots are shown in Figure 1, Supplementary
Material,Figures S1 and S2, and the top associated haplotypesand
SNPs are listed in Tables 1 and 2, respectively.
Association
LRRK2
The strongest SNP association signal was detected at the LRRK2
locus [rs1442190, OR ¼ 3.72 (2.98, 4.64), P ¼ 1.53 × 10227,
Fig. 2A]. The best associated DASH segment refines this
signal with OR ¼ 12.05 (8.35, 17.41) and P ¼ 1.23 × 10256.
We found 170 copies of this segment in PD cases and 35 in con-
trols, which accounted for all known p.G2019S PD cases in our
cohort (independently genotyped, see Supplementary Material,
Table S2). The two pericentromeric association signals on
chr12 reported in Tables 1 and 2 are due to long-range LD in
this region (chr12:33–40 Mb) (26). There was no residual
signal on chr12 after conditioning on the independently geno-
typed p.G2019S carrier status, indicating that in our cohort,
p.G2019S is responsible for the association at the LRRK2 locus.
Chr17q21.31/MAPT
Strong association signal coming from both SNPs [rs17577094,
OR ¼ 0.64 (0.56, 0.72), P ¼ 4.51 × 10210] and DASH seg-
ments [OR ¼ 0.62 (0.54, 0.72), P ¼ 1.78 × 10211, shared by
423 cases and 1351 controls] was observed within the 900-kb in-
version polymorphism on chr17q21.31 (27). Association to PD
at this locus has been previously reported in a European cohort
(rs393152; OR ¼ 0.77; P ¼ 1.95 × 10216) (7) and replicated
in a subset of our Ashkenazi samples [OR ¼ 0.54 (0.49, 0.74),
P ¼ 7.16 × 1025] (28). The inverted haplotype (H2) frequency
in Europeans varies in a gradient away from the Mediterranean
Sea (37.5% in Sardinians to 4.3% in Finns) and is 25.6% in Ash-
kenazi Jews (29). H1 and H2 haplotypes do not recombine and
are well tagged by common SNPs, which causes a peculiar LD
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Figure 1.Manhattan plots showing the association of (A) imputed SNPs and (B) DASH segments. Lower panels show association results conditioned on the LRRK2
andGBAmutation carrier status, for (C) imputed SNPs and (D) DASH segments. Markers color-coded red surpass the Bonferroni-corrected genome-wide significance
thresholds.
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pattern as seen in Figure 2B and leads to a smaller disparity in the
association signals coming from SNPs and DASH segments.
Upon conditioning on an inversion marker (rs1800547/
C7563692) (30), there is no haplotype association signal remain-
ing at this locus (P ¼ 0.037), the SNP association signal for
rs17577094 decreases (P ¼ 1.29 × 1025) and association of
SNPs in LD vanishes (Supplementary Material, Fig. S3), sug-
gesting that the inversion event acts as an excellent tag for the
causal variant at this locus.
GBA
We captured a genome-wide significant association signal at the
GBA locus [rs1630500, OR ¼ 1.75 (1.43, 2.15), P ¼ 2.12 ×
1028, Fig. 2C]. Analysis of DASH segments and comparison
with the independently genotyped GBA mutations revealed
several distinct groups of associated haplotypes. An IBD
segment of 808 kb in length that carries the c.84dupG (84GG)
mutation [Haldane-corrected OR¼ 51.28 (8.28, 2094.86), P ¼
1.13 × 10211] occurs in 21 cases and no controls. Following
in significance are DASH segments proximal and distal to the lo-
cation of the GBA gene, one seen in 96 cases and 88 controls
[OR ¼ 2.50 (1.87, 3.35), P ¼ 1.22 × 1029] and the other seen
in 193 cases and 256 controls [OR ¼ 1.82 (1.50, 2.20), P ¼
1.62 × 1029], both featuring p.N370S mutation carriers.
Samples in the proximal segment are a subset of samples in the
distal segment. A DASH segment between these two contains a
haplotype shared by all p.N370S carriers; however, it contains
additional cases and controls and shows a weaker association to
PD [OR ¼ 1.65 (1.37, 1.97), P ¼ 1.22 × 1027]. The shared
IBD segment that carries the p.R496H mutation did not reach
genome-wide significance [OR ¼ 4.07 (2.00, 8.29), P ¼ 7.82 ×
1025] owing to the small number of p.R496H carriers in our
cohort. After conditioning on the GBA mutation carrier status
(Supplementary Material, Methods), we did not observe any re-
sidual association signal at the GBA locus.
Chr2q14.3
A novel genome-wide significant rare DASH segment
of 500 kb in length, shared by 24 cases and three controls,
was observed on chr2q14.3 [OR ¼ 22.58 (6.69, 119.15),
P ¼ 1.21 × 10210, Fig. 2D]. We trained a decision tree classifier
to discriminate haplotype carriers from non-carriers (Supple-
mentary Material, Methods). When we applied the four-SNP
haplotype model (rs1921815, rs6742628, rs11679636 and
rs17010715, highlighted in red in Supplementary Material,
Table S3) to a secondary cohort of 306 Ashkenazi PD cases
and 2583 controls, we found the haplotype present in 13.1
(95% CI 9.2, 16.9) cases and 0 controls, which corresponds
to the replication Fisher’s exact P ¼ 1.68 × 10213 (1.51 ×
1029, 1.77 × 10217). The only annotated gene within 1 Mb on
either side of the DASH segment is contactin-associated protein-
like 5 CNTNAP5, a member of the neurexin family of cell adhe-
sion molecules and receptors, expressed in vertebrate neurons.
CNTNAP5has been previously implicated in neurodevelopmen-
tal phenotypes (31); however, its functional relatedness to PD is
not apparent. We sequenced the first 10 exons ofCNTNAP5 that
were within the boundaries of the haplotype and observed an
SNP in the 5′ UTR of the CNTNAP5 gene at position
chr2:124499 401 (rs77182849), present in all five PD cases
that were sequenced and an intronic SNP at chr2:124 920 755,T
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seen in only two out of the five sequenced samples (Supplemen-
tary Material, Table S4). We did not identify any coding variants.
According to the 1000 Genomes Project, MAF of rs77182849 is
5% across all ethnic groups and 11% in samples of European an-
cestry, making it unlikely to be a rare risk allele for PD.
Additional association signals
We observed an SNP hit on chr1q32.1, in the PARK16 locus
[rs823114; OR ¼ 0.75 (0.68, 0.83), P ¼ 2.76 × 1026], with an
effect consistent with the one seen in non-Jewish Europeans
(rs823128, OR ¼ 0.66) (7), and recently in two cohorts of Ash-
kenazi PD patients and controls (28,32). The best DASH
segment at this locus captures a rare haplotype that occurs
in 11 cases and 2 controls [OR ¼ 12.77 (2.83, 57.64), P ¼
7.69 × 1025, Supplementary Material, Fig. S4].
Among the three common loci that were nearing signifi-
cance—chr2q31.1, chr4q31.3 and chr16p11.2 (Table 2)—that
we attempted to replicate in the secondary cohort, we observed
moderate replication signal at chr2q31.1 (P ¼ 0.012), in the
intergenic region between cell division cycle-associated seven
gene CDCA7 and Sp3 transcription factor gene SP3.
Two additional genome-wide significant rare DASH seg-
ments on chr5q31.1 [OR ¼ 44.25 (5.92, 330.90), P ¼ 1.79 ×
1029] and chr18q12.2 [OR ¼ 12.82 (4.41, 37.25), P ¼ 1.31 ×
1028] did not replicate in the secondary cohort (Supplementary
Material, Tables S5 and S6).
Homozygosity mapping, typically informative in studies of
founder populations, in our study did not implicate any regions
at the genome-wide significance level.
Clinical and demographics variables
Information about sex, age-at-onset (AAO, defined as the age of
first symptoms) and whether the case was sporadic or familial
(defined as having a first degree relative with PD) is summarized
in Supplementary Material, Table S2. Columbia had a higher
fraction of male PD cases (67.4% compared with 56.1 and
62.6%,x2P ¼ 4.3 × 1025), and Beth Israel had a higher fraction
of familial cases (38.6% compared with 17.8 and 16.8%, x2
P ¼ 2.7 × 10211). There was no significant difference in the
AAO between the three centers (logrank P ¼ 0.55, Supplemen-
tary Material, Fig. S6A). The differences in family history are
likely because of differences in sampling strategy between the
three centers: predilection towards early onset PD cases at
Columbia, towards familial cases at Beth Israel and consecutive
recruitment at Tel Aviv Sourasky.
The average p.G2019S carrier frequency was 14.9% (Supple-
mentary Material, Table S2). Although some heterogeneity was
observed among centers (19.8, 13.3 and 14.0% in Beth Israel,
Columbia and Tel Aviv Sourasky cohorts, respectively), it was
not statistically significant (Fisher’s exactP ¼ 0.085). Observed
frequency of p.G2019S is similar to what was previously pub-
lished (14.8%), although we should note that there is a sample
overlap between this and the previous study. The frequency of
GBA mutation carriers was 17.6% in the combined sample,
with significant heterogeneity between centers (12.0, 16.7 and
20.2%, P ¼ 0.021), and not significantly different from the
previously published frequency range of 13.7–17.9% (12,18),
although again some samples overlapped between this and the
earlier study.
LRRK2 and GBA mutation carriers have an earlier AAO than
non-carriers (mean + SD, 56.4+ 11.7 and 54.0+ 11.3%, re-
spectively, compared with 60.6+ 11.6%, logrank P ¼ 1.2 ×
1025, Supplementary Material, Fig. S6B). Familial cases are
enriched in LRRK2 mutation carriers (29.1% of familial cases
carry p.G2019S,P ¼ 7.15 × 1029), comparable to the previous-
ly published estimate of 26%, but are not enriched in GBA car-
riers. We did not observe evidence in support of a gender
effect for either LRRK2 (P ¼ 0.098) or GBA (P ¼ 0.70), and
there was no difference in AAO between males and females
(P ¼ 0.97), nor between familial and sporadic cases (P ¼ 0.27,
Kaplan–Meier curves are shown in Supplementary Material,
Fig. S6).
To investigate genetic factors that may influence clinical and
demographic variables, we performed case-only genome-wide
associations to family history, gender and AAO using Fisher’s
exact and logrank tests. We did not observe any site that
increases gender-specific risk (Supplementary Material,
Fig. S7). The only locus strongly associated with familial
forms of PD was LRRK2 (Supplementary Material, Fig. S8).
One locus on chr17q24.2 captured by DASH segments in three
samples had a genome-wide significant effect on AAO
(chr17:62 661 453–63 110 659; mean+SD 92.7+ 1.5, P ,
1.0 × 1028, Supplementary Material, Figs S9C and S10). It con-
tains two genes, proteasome 26S subunit (PSMD12) and cyto-
plasmic phosphatidylinositol transfer protein, cytoplasmic
(PITPNC1).
Table2. Imputed SNPs associated with PD, with EMMAXP-value of,3.0 × 1026 either unconditioned and conditioned onLRRK2 andGBAmutation carrier status
SNP Chromosome Position Gene/
locus
Alleles MAF (%)
PD
MAF (%)
controls
OR
(95% CI)
P-value
(unconditional)
P-value
(conditional)
P-value
(replicated)
rs1442190 12 39 651 907 LRRK2 T/C 9.16 2.64 3.72 (2.98, 4.64) 1.53 × 10227 0.184 –
rs10506095 12 32 691 394 LRRK2 A/G 7.88 2.60 3.20 (2.54, 4.02) 1.36 × 10220 0.499 –
rs17577094∗ 17 41 543 275 MAPT C/T 18.50 26.25 0.64 (0.56, 0.72) 8.33 × 1029 4.51 × 10210 –
rs1630500 1 153 121 679 GBA A/G 7.70 4.54 1.75 (1.43, 2.15) 2.12 × 1028 0.036 –
rs10737170 1 154 330 504 GBA C/A 19.25 13.83 1.49 (1.30, 1.69) 8.62 × 1028 0.725 –
rs7185232 16 28 840 969 16p11.2 G/A 20.27 26.45 0.71 (0.63, 0.80) 1.38 × 1027 1.98 × 1025 0.27
rs823114 1 203 986 155 PARK16 G/A 34.82 41.54 0.75 (0.68, 0.83) 2.76 × 1026 0.000683 –
rs1813134∗ 4 151 450 821 4q31.3 A/G 35.13 29.68 1.28 (1.16, 1.43) 5.69 × 1026 4.33 × 1027 0.64
rs6739381∗ 2 174 249 536 2q31.1 T/C 11.02 8.16 1.39 (1.18, 1.64) 3.58 × 1025 9.58 × 1027 0.012
Only the single strongest associated SNP at each peak has been reported. For the three SNPs that had stronger association in the conditional analysis (marked with ∗),
ORs and 95% CI are based on Mantel–Haenszel pooled odds ratios; otherwise they were single stratum sample ORs.
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Figure 2.Association of imputed SNPs and DASH segments at the four genome-wide significant loci either also associated in other studies, or replicated as part of this
study: (A) chr12q12 (with the associated LRRK2 gene), (B) chr17q21 (MAPT), (C) chr1q21 (GBA) and (D) chr2q14 (CNTNAP5).
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Replication of previously published loci
In order to evaluate the overlap between genetic risk factors con-
tributing to PD in Ashkenazi Jews and other populations, we
tested all hits with P-values of ,1025 reported in previously
published GWASs (3,5–7,33,34). For the first time in the Ash-
kenazim, we observed an association signal at the SNCA locus
[rs356220; OR ¼ 1.22 (1.11, 1.35), P ¼ 5.6 × 1025], with an
odds ratio comparable to that in Europeans (1.23–1.30). At the
significance level Bonferroni-corrected by the number of SNPs
that we attempted to replicate (a ¼ 0.05/66 ¼ 0.00076), we
were able to capture association signals at the MCCC1/LAMP3
[rs9290751; OR ¼ 0.80 (0.71, 0.91), P ¼ 3.55 × 1024] and
PARK16 loci [rs947211; OR ¼ 0.77 (0.69, 0.87), P ¼ 6.68 ×
1024]. At the nominal significance level, we were able to
capture four additional signals (GAK/DGKQ, RIT2/SYT4,
ITGA8 and CCDC62/HIP1R, Supplementary Material,
Table S7).
In addition, association of IBD segments was able to capture
signals at theGAK/DGKQ andBST1 loci (Supplementary Mater-
ial, Table S8). At theBST1 locus—similar to what we observed at
the GBA locus—there was more than one distinct group of hap-
lotypes carrying the variants that increase the risk of PD: chr4:14
997 475–15 727 723 [OR ¼ 23.2 (3.0, 181.4), P ¼ 4.98 ×
1025, 0.44% in PD, 0.019% in controls] and chr4:15 215 529–
15 350 349 [OR ¼ 2.2 (1.3, 3.6), P ¼ 0.0018, 1.4% in PD,
0.65% in controls]. However, when we corrected the nominal
P-values by the number of DASH segments at the GAK/
DGKQ and BST1 loci and the number of loci tested genome
wide, these two hits were not significant. Nonetheless, carriers
of the BST1 segments, and in particular the high-risk haplotype,
are interesting candidates for sequencing follow-ups.
Using both association strategies, we were able to replicate
known signals at three loci (SNCA, MCCC1/LAMP3 and
PARK16), and we have seen nominal significance at five add-
itional loci (GAK/DGKQ, RIT2/SYT4, ITGA8, CCDC62/
HIP1R and BST1). Together with the loci genome-wide signifi-
cant in this study, we have in all been able to capture association
signals at 11 out of 33 currently known PD loci. Top SNPs at the
three genome-wide significant loci (LRRK2, GBA and MAPT)
taken together explain 8.1% of phenotypic variance (Nagelk-
erke’s pseudo R2 from logistic regression), and top SNPs at
seven loci with replication P-value of ,0.05 (PARK16,
MCCC1/LAMP3, GAK/DGKQ, SNCA, ITGA8, CCDC62/
HIP1R and RIT2/SYT4) explain additional 2.0%, for a total of
10.1%. Genome-wide significant and replicated DASH seg-
ments (LRRK2, GBA, MAPT and CNTNAP5) explain 15.6% of
the phenotypic variance and, together with the segments that
have corrected P-values of ,0.05, explain a total of 16.5% of
phenotypic variance. As expected, this is significantly higher
than variance explained in outbred European populations, esti-
mated to be 6–7% (3).
DISCUSSION
We have identified genome-wide significant haplotypes at
LRRK2, GBA, MAPT and chr2q14.3 loci, ranging in size from
40 to 800 kb. The first three of these were previously known
and were also captured using imputed SNPs as part of our
study; however, haplotype associations consistently refined the
SNP association signals. In addition, we replicated SNPs at
SNCA, MCCC1/LAMP3 and PARK16 loci. An earlier GWAS
conducted on partially overlapping set of samples (268 cases
and 178 controls ascertained at Columbia University Medical
Center) replicated association signals at the MAPT (P ¼
7.16 × 1025), LRRK2 (P ¼ 1.56 × 1024), PARK16 (P ¼
6.12 × 1024) andGBA loci (seven SNPs with nominally signifi-
cant P-values); however, owing to the small sample size, it was
underpowered to reach genome-wide significance at any locus
(28). Interestingly, we were not able to replicate the exact previ-
ously reported SNPs at the LRRK2 and GBA loci, although
LRRK2 and GBA were genome-wide significant in our study.
This points to the differences in LD structure between the Ash-
kenazim and non-Jewish Europeans at these two loci.
A point worth making is that we did not observe a significant
p.N370S DASH segment that overlaps the GBA gene, although
two significant p.N370S DASH segments were found proximal
and distal to the GBA gene. This may indicate a limitation of
our method to resolve haplotypes in a complex genetic region,
or a possibility that there might be additional mutations contrib-
uting to the risk of PD, linked with p.N370S, located within the
flanking DASH segments. We observed a secondary distal
linked SNP signal [rs10737170; OR ¼ 1.49 (1.30, 1.69); P ¼
8.62 × 1028] that corresponds to the distal DASH segment;
however, after conditioning on the GBA mutation carrier
status, there was no residual signal at the GBA locus. On the
other hand, a recent study reported an association hit in
Europeans [OR ¼ 1.67 (1.50, 1.84), P ¼ 5.7 × 1029] related
to the nearby SYT11 gene (5), close to GBA but apparently inde-
pendent of the mutations in GBA in Europeans.
Assembling a sizeable cohort of samples from the Ashkenazi
Jewish founder population came at the expense of genotyping
platform heterogeneity, which had to be carefully addressed.
To provide a uniform, dense set of markers, we created a
custom Ashkenazi reference panel (22) and imputed the
missing SNPs. Pooling samples and imputation of missing
SNPs, as opposed to a more straightforward meta-analysis,
allowed consistent quality control across all samples and
enabled us to phase SNPs and call shared IBD segments. Some
of the control samples used in this study were diagnosed with
Crohn disease (CD); nonetheless, CD and PDs are clinically,
pathologically and etiologically distinct, and for the variants
reported in this study, we did not observe significant differences
in allele frequencies between healthy controls and Crohn cases
(Supplementary Material, Table S9 and S10). Although variants
at LRRK2 and HLA loci have been associated with both PD and
CD, separate analysis of PD and CD in our cohort showed no
overlap in terms of risk loci, which together with the increase
in power coming from having a larger number of control
samples (Supplementary Material, Fig. S5) justifies the use of
CD cases as non-Parkinson controls. In addition, we concurrent-
ly performed a GWAS of CD in Ashkenazi Jews (22), and this
provided an opportunity to verify the association signals. In con-
trast to CD, which has population prevalence two to four times
higher in the Ashkenazi Jews compared with non-Jewish Eur-
opeans, and several rare disorders (such as Tay-Sachs and
Gaucher diseases) that appear at elevated frequencies among
the Ashkenazim, limited surveys of PD prevalence remain in-
conclusive. One study found no significant difference between
Ashkenazi Jews and non-Jewish Europeans (35). A more
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recent study indicated that PD prevalence in Israel is elevated
compared with Europe and the USA (36), although it did not spe-
cifically focus on the Ashkenazim.
Our results highlight the usefulness of our haplotype associ-
ation method. Until whole-genome sequencing in large cohorts
becomes widespread, associated DASH segments can be used
to guide targeted region resequencing efforts or to prioritize
samples for whole-genome sequencing. Although the use of
DASH is not limited to founder populations, pervasive IBD
sharing in these populations facilitates haplotype mapping, as
demonstrated here. DASH was able to dissect the signal at the
GBA locus into distinct groups of haplotypes that carry distinct
mutations and provide initial evidence that multiple causal var-
iants might also be present at the BST1 locus. We were also able
to identify and replicate a novel risk haplotype on chr2q14.3 oc-
curring at1% frequency in PD cases. This haplotype contains a
single gene expressed in the brain, CNTNAP5, previously not
implicated in PD. As rare alleles tend to be population-specific,
it remains to be seen whether the risk variant that arose on the
backbone of this haplotype, or possibly different variants in
the CNTNAP5 gene, are present in other populations. Taken to-
gether, our results reaffirm the complex genetic background of
PD and emphasize the need for studying both common and
rare variants in PD, with the goal of understanding the molecular
processes these variants affect.
MATERIALS AND METHODS
The study was approved by the Institutional Review Boards at all
participating institutions, including Beth Israel Medical Center,
Columbia University, Tel Aviv Sourasky Medical Center, Mount
Sinai School of Medicine, Albert Einstein College of Medicine,
The Hebrew University of Jerusalem, Yale University, Children’s
Hospital of Philadelphia and North Shore University Hospital-
Long Island Jewish Medical Center. All patients provided
written informed consent (in English or Hebrew) for the collection
of samples and subsequent analysis.
Primary cohort
A total of 1248 Ashkenazi PD cases have been ascertained at Tel
Aviv Sourasky Medical Center (Tel Aviv, Israel), Center for
Movement Disorders at Columbia University and Department
of Neurology at Beth Israel Medical Center (New York, USA).
Subjects at Tel Aviv Sourasky Medical Center (n ¼ 597) were
consecutively recruited individuals of Ashkenazi Jewish
origin; details of the cohort recruitment, diagnostic criteria and
interview procedures are as described in (12,14). The cohort of
cases recruited at the Center for Movement Disorders at Colum-
bia University was created by combining participants from two
studies of PD: genetic Epidemiology of PD (n ¼ 168, enriched
for cases with AAO , 50 y/o) and the Ashkenazi Jewish PD
study (n ¼ 184, selected based on self-reported ancestry).
Details of the ascertainment procedures, evaluation criteria
and structured interviews are provided in (28,37). Ashkenazi
PD cases recruited from the Department of Neurology at Beth
Israel (n ¼ 299) have been evaluated as previously described
in (15). PD cases that carried mutations in the GBA gene did
not have symptoms of Gaucher Disease. To account for
differences in procedures employed to verify subjects’ Ashken-
azi Jewish ancestry at different centers, as part of this study
ancestry of all subjects was uniformly verified using princi-
ple component analysis. Our recent results justify the use of
a single population model for Ashkenazi Jews from Israel
and the USA (38) and show that after accounting for Euro-
pean admixture, there is no evidence for significant population
stratification (39).
The set of 2865 Ashkenazi controls contain both neurologic-
ally healthy individuals (n ¼ 422) from Tel Aviv Sourasky, Col-
umbia and Beth Israel Medical Centers and pooled controls who
have not undergone neurological examination (n ¼ 2443) from
The Hebrew University of Jerusalem, Albert Einstein College
of Medicine, Mt. Sinai School of Medicine, Yale University
and Children’s Hospital of Philadelphia. Pooled controls
consist of apparently healthy individuals (controls in their re-
spective studies, n ¼ 1474) as well as individuals diagnosed
with CD (n ¼ 969). A subgroup of the apparently healthy
pooled controls (n ¼ 646) was recruited for a study of healthy
aging (40). Based on PD population prevalence of 1% (41),
24 pooled control samples can be expected to have or will
have developed PD. Details of the sample cohorts are summar-
ized in Supplementary Material, Table S1.
Samples were genotyped on Illumina Human 300 k,
500 k, 660 k and Omni1M and Affymetrix GeneChip Human
Mapping 500K and Genome-Wide Human SNP 6.0 arrays (Sup-
plementary Material, Table S1). Details about quality control,
ancestry filtering, etc., are provided in Supplementary Material,
Methods.
Replication cohort
A selected set of SNPs was genotyped in the replicate cohort of
306 Ashkenazi PD cases from Tel Aviv Sourasky Medical
Center using ABI TaqMan assays (Applied Biosystems, Foster
City, CA, USA). Frequencies of LRRK2/GBA mutations in the
replicate PD cohort were comparable to the primary sample.
Replication controls consisted of 2583 Ashkenazi schizophrenia
cases and controls from the North Shore-Long Island Jewish
Health System typed on Illumina HumanOmni1-Quad Bead-
Chip, imputed using the same procedure and passing the same
quality control and ancestry filtering as the discovery cohort.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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